R1 Therapeutics Launches with $77.5M Series A to Advance CKD Treatment
Redwood City, CA – March 17, 2026 – R1 Therapeutics has officially emerged from stealth mode, announcing an oversubscribed...
First-in-Class Therapy
Advertisement
IDEAYA Biosciences Enrolls First Patient in Phase 1/2 Combination Trial of IDE397 and Trodelvy® in MTAP-Deletion NSCLC
IDEAYA Biosciences, Inc. (Nasdaq: IDYA), a precision medicine oncology company, announced the enrollment of the first patient in its...
Advertisement
